Grolleau A, Cougnard A, Parrot M, Kalmi E, Desage A, Misdrahi D, Brun-Rousseau H, Verdoux H
Université Victor-Segalen Bordeaux 2, Bordeaux, France.
Encephale. 2007 May-Jun;33(3 Pt 1):326-31. doi: 10.1016/s0013-7006(07)92046-1.
The aims of this pharmacoepidemiological study were to describe the antipsychotic medication received during the first admission and over a two-year follow-up in subjects with a first episode of psychosis, and to assess whether the prescriptions in naturalistic conditions were in adequacy with guidelines.
All first-admitted patients, less than 50 years old, consecutively hospitalised in 10 acute wards of two psychiatric hospitals serving Bordeaux's catchment area were included over a period of one year, if they presented with at least one overt psychotic symptom during the last month. Information on psychotropic medication received during the first admission was collected in medical records, and that received after the first admission was collected at the end of a two-year follow-up using multiple sources of information.
Of the 86 patients included in the cohort, 53 presented with broadly defined schizophrenia and 33 with psychotic mood disorder. All except two subjects were prescribed at least one neuroleptic drug. Antipsychotic drugs (amisulpride, olanzapine, risperidone, clozapine) were the most frequently prescribed drugs during the first admission and over the two-year follow-up. If sedative neuroleptics were excluded, antipsychotic drugs were the first prescribed neuroleptic drugs in a large proportion (80%) of patients. Although few patients were first prescribed a conventional neuroleptic, the proportion of subjects treated with these drugs increased over the next prescriptions, and one out of three patients was prescribed at least one of these drugs during the follow-up. The mean dose of antipsychotic drugs at first discharge was higher than that recommended in first episode patients (amisulpride 616 mg, olanzapine 13 mg, risperidone 7 mg). Coprescription of neuroleptic drugs, found in one third of patients at all times of assessment, was especially due to coprescription of a sedative neuroleptic to a conventional or an antipsychotic one. Nearly half of the patients did not take any psychotropic medication at the end of the follow-up.
The main recommendation specifying that the first neuroleptic treatment in subjects with a first episode of psychosis should use antipsychotic drugs instead of conventional neuroleptics was generally respected in this cohort of first-admitted subjects with psychosis. However, conventional neuroleptics were found in first or second rank prescriptions, although they should not be used before at least the third rank. The recommendations that the initial neuroleptic dose should be lower in subjects with a first episode, and that coprescription of neuroleptics should be avoided, were frequently not respected. This study highlights the fact that international guidelines should be better applied in naturalistic conditions, and that clinicians have to be better informed about these recommendations.
本药物流行病学研究旨在描述首次发作精神病患者首次入院期间及两年随访期间所接受的抗精神病药物治疗情况,并评估自然状态下的处方是否符合指南。
在一年时间内,纳入了在波尔多市服务区域内两家精神病医院的10个急性病房连续住院的所有年龄小于50岁的首次入院患者,前提是他们在过去一个月内至少出现一种明显的精神病症状。首次入院期间接受的精神药物信息从病历中收集,首次入院后接受的精神药物信息在两年随访结束时通过多种信息来源收集。
该队列纳入的86例患者中,53例患有广义定义的精神分裂症,33例患有精神病性心境障碍。除两名患者外,所有患者均至少开具了一种抗精神病药物。抗精神病药物(氨磺必利、奥氮平、利培酮、氯氮平)是首次入院期间及两年随访期间最常开具的药物。如果排除镇静性抗精神病药物,抗精神病药物在很大比例(80%)的患者中是首次开具的抗精神病药物。虽然很少有患者首次开具传统抗精神病药物,但在后续处方中接受这些药物治疗的患者比例增加,并且在随访期间三分之一的患者至少开具了其中一种药物。首次出院时抗精神病药物的平均剂量高于首次发作患者的推荐剂量(氨磺必利616毫克,奥氮平13毫克,利培酮7毫克)。在所有评估时间点,三分之一的患者存在抗精神病药物的联合处方,尤其是将镇静性抗精神病药物与传统或抗精神病药物联合使用。近一半的患者在随访结束时未服用任何精神药物。
本队列中首次入院的精神病患者普遍遵循了主要建议,即首次发作精神病患者的首次抗精神病药物治疗应使用抗精神病药物而非传统抗精神病药物。然而,尽管传统抗精神病药物不应在至少第三级之前使用,但在首次或第二级处方中仍发现了它们。首次发作患者初始抗精神病药物剂量应较低以及应避免抗精神病药物联合处方的建议经常未被遵循。本研究强调了在自然状态下应更好地应用国际指南这一事实,并且临床医生必须更好地了解这些建议。